Filters

A J Scheen
M Moutschen

Showing results (81-90 of 679) with videos related to

Pageof 68
Sort By:
Revue Medicale De Liege|May 10, 2000
[Antioxidant vitamins in the prevention of cardiovascular diseases. First part: epidemiologic studies]A J Scheen
Revue Medicale De Liege|May 8, 2001
[Pharmacy clinics. Medication of the month. Clopidogrel (Plavix)]A J Scheen
Diabetes & Metabolism|February 2, 2019
Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: A common comorbidity associated with severe complicationsA J Scheen
Revue Medicale De Liege|December 30, 2004
[Withdrawal of rofecoxib (Vioxx): what about cardiovascular safety of COX-2 selective non-steroidal anti-inflammatory drugs?]A J Scheen
Revue Medicale Suisse|October 5, 2005
[Triple oral therapy in type 2 diabetes]A J Scheen
Revue Medicale De Liege|March 1, 2013
[Limited add-on value of oral glucose-lowering agents in type 1 diabetes]A J Scheen
Revue Medicale De Liege|December 8, 2015
[EMPAGLIFLOZIN (JARDIANCE) :Nw SGLT2 COTRANSPORTER INHIBITOR FOR TREATING TYPE 2 DIABETES]A J Scheen
Revue Medicale De Liege|June 3, 2021
[Environment and cancer : not easy to dissect the exposome !]A J Scheen
Diabetes & Metabolism|January 18, 2006
Diabetes mellitus in the elderly: insulin resistance and/or impaired insulin secretion?A J Scheen
Revue Medicale De Liege|April 7, 2017
[Dapagliflozin (forxiga®) : SGLT 2 cotransporter inhibitor as glucose-lowering agent in type 2 diabetes]A J Scheen
Pageof 68

Showing results (81-90 of 679) with videos related to

Sort By:
Pageof 68
Revue Medicale De Liege|May 10, 2000
[Antioxidant vitamins in the prevention of cardiovascular diseases. First part: epidemiologic studies]A J Scheen
Revue Medicale De Liege|May 8, 2001
[Pharmacy clinics. Medication of the month. Clopidogrel (Plavix)]A J Scheen
Diabetes & Metabolism|February 2, 2019
Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: A common comorbidity associated with severe complicationsA J Scheen
Revue Medicale De Liege|December 30, 2004
[Withdrawal of rofecoxib (Vioxx): what about cardiovascular safety of COX-2 selective non-steroidal anti-inflammatory drugs?]A J Scheen
Revue Medicale Suisse|October 5, 2005
[Triple oral therapy in type 2 diabetes]A J Scheen
Revue Medicale De Liege|March 1, 2013
[Limited add-on value of oral glucose-lowering agents in type 1 diabetes]A J Scheen
Revue Medicale De Liege|December 8, 2015
[EMPAGLIFLOZIN (JARDIANCE) :Nw SGLT2 COTRANSPORTER INHIBITOR FOR TREATING TYPE 2 DIABETES]A J Scheen
Revue Medicale De Liege|June 3, 2021
[Environment and cancer : not easy to dissect the exposome !]A J Scheen
Diabetes & Metabolism|January 18, 2006
Diabetes mellitus in the elderly: insulin resistance and/or impaired insulin secretion?A J Scheen
Revue Medicale De Liege|April 7, 2017
[Dapagliflozin (forxiga®) : SGLT 2 cotransporter inhibitor as glucose-lowering agent in type 2 diabetes]A J Scheen
Pageof 68
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us